Mavacamten – Medxy AI

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

By MedXY 12/24/2025

While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesting a potent biological effect on myocardial wall stress and chronic injury.

Cardiology news Specialties

Evaluating Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM Trial

By MedXY 09/10/2025

A phase 3 trial found mavacamten did not significantly improve exercise capacity or symptoms in adults with symptomatic nonobstructive hypertrophic cardiomyopathy compared to placebo, despite its efficacy in obstructive HCM.

Cardiology news Specialties

Long-Term Benefits and Safety of Mavacamten in Obstructive Hypertrophic Cardiomyopathy: Insights from the VALOR-HCM 128-Week Study

By MedXY 08/17/2025

The VALOR-HCM trial demonstrates that mavacamten sustains symptomatic improvement and significantly reduces septal reduction therapy (SRT) need over 128 weeks in severely symptomatic obstructive hypertrophic cardiomyopathy patients.